The patients in the maintenance group received maintenance chemotherapy with S-1 ( 40 mg/m ( 2 ) , twice daily for 14 days ; 21 days for a treatment cycle ) until disease progression or with intolerant toxicity , and those in the control group received optimal supportive care .